Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

IF 22.5 1区医学 Q1 ONCOLOGY

JAMA Oncology Pub Date : 2024-04-18 DOI:10.1001/jamaoncol.2024.0473

Laurent Phely, Luca Hensen, Christoph Faul, Christer Alexander Ruff, Dina Schneider, Wolfgang Andreas Bethge, Claudia Lengerke

引用次数: 0

Abstract

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

查看原文本刊更多论文

异体 CD19/CD22 CAR T 细胞疗法治疗 B 细胞急性淋巴细胞白血病

本系列病例报告了两名接受异体双特异性 CD19/CD22 靶向嵌合抗原受体 T 细胞治疗的复发/难治性 B 细胞急性淋巴细胞白血病患者的持久缓解情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.